Search this site

Dr. Hossam Abdel Maksoud Chief Executive Officer Mohamed AlNadi Vice President, International Expansion and Partnerships (MENA and Africa) Stephen Lawandy Global Head of Strategy & Investor Relations Thomas Ingallinera Vice President of Operations Mathew Cherian Chief Operating Officer Dr. Helmy Nada Fund Manager, Dawah Holdings

Strategic Partnerships Driving Global Pharmaceutical Impact At Dawah Pharmaceuticals, partnerships are more than just collaborations — they are long-term alliances built on shared values, innovation, and a deep commitment to advancing human health. JOIN US Dawah-Holdi International Dawah-Holdi International is a strategic joint venture between Dawah Pharmaceuticals and HoldiPharma, combining extensive pharmaceutical expertise and innovative manufacturing capabilities. This partnership leverages HoldiPharma's robust manufacturing infrastructure in Egypt with Dawah Pharmaceuticals' regulatory knowledge and market access to the United States, creating a synergistic approach to deliver high-quality, FDA-compliant generic medications. Dawah-Gypto International Dawah-Gypto International is a dedicated joint venture between Dawah Pharmaceuticals and Gypto Pharma, one of Egypt’s premier pharmaceutical manufacturing companies. The partnership focuses on modernizing production lines to meet stringent FDA standards, thereby facilitating the export of quality pharmaceutical products from Egypt to the U.S. This strategic collaboration uniquely positions Dawah-Gypto International to deliver cost-effective generic medications that adhere strictly to U.S. regulatory guidelines. QG International QG International is a strategic joint venture between Dawah Pharmaceuticals and QG Medical Devices, one of the Middle ,East's leading manufacturers of advanced medical devices .headquartered in Doha, Qatar This partnership aims to integrate Dawah's pharmaceutical expertise with QG's state-of-the-art production capabilities deliver high-quality, FDA-compliant medical devices and healthcare pipeline solutions. By combining Dawah's strong regulatory foundation and global network with QG's technological innovation and precision engineering, the collaboration paves the way for enhanced accessibility and affordability of world-class medical solutions across regiona .and international markets

Strategic Partnership Signed Between Dawah Pharma LLC (USA) and Bateel Group Holding A strategic partnership agreement has been signed in Cairo between Dawah Pharma LLC (USA) and Bateel Group Holding, in the presence of key industry and government representatives. The agreement aims to upgrade pharmaceutical production lines in compliance with FDA standards and introduce new investments to support the export of Egyptian pharmaceuticals to global markets. This milestone builds on Dawah Pharma’s successful collaborations in Egypt with Gypto Pharma City and Dawah Holdi, reinforcing its commitment to enhancing the competitiveness of the Egyptian pharmaceutical industry, transferring global technologies, and strengthening Egypt’s position as a leading regional hub for pharmaceutical manufacturing and export

Mathew Cherian Chief Operating Officer Mathew Cherian is the Chief Operating Officer and Co-Founder of the company, bringing more than 34 years of international experience in the pharmaceutical industry across the United States and Europe. Before co-founding the organization, Mr. Cherian served as Director and Senior Fellow at a leading global pharmaceutical company. During his tenure, he played a key role in early stage product development and successfully coordinated research efforts across multiple global Pfizer sites. His extensive expertise in complex pharmaceutical products continues to support the development of innovative therapies across several therapeutic areas. Mr. Cherian is a recognized expert in drug device combination products and is a leader in advancing differentiated drug delivery systems, contributing to the development of high-value, advanced pharmaceutical solutions. He holds a Ph.D. in Chemical Engineering from the University of Rhode Island and is an inventor with multiple patents. Widely regarded as a thought leader in the industry, he regularly speaks at global pharmaceutical forums and serves on the Executive Committee of the International Pharmaceutical Society. enhance community well being.

Mohamed AlNadi Vice President, International Expansion and Partnerships (MENA and Africa) Dr. Mohamed Alnadi serves as the Vice President of International Expansion and Partnerships for the MENA and Africa regions. With over 25 years of experience in international trade, export operations, and strategic market growth, he has successfully expanded business footprints across more than 60 countries. Since 2002, Dr. Alnadi has led Alnadi Pharmacy Company, establishing it as a trusted name in the pharmaceutical and healthcare sectors. He previously held the position of Managing Director at EgyBelg for Industrial Investment, where he specialized in biotechnology and enzyme production. He also managed a leading food manufacturing company, driving its expansion across regional and global markets. Dr. Alnadi holds a Bachelor’s degree in Pharmacy from Cairo University and a Business Administration Diploma from the American University in Cairo.

Egypt Signs Strategic Tripartite Partnership to Build an Integrated Medical Manufacturing Ecosystem for Regional & Global Markets Read More Strategic Partnership Signed Between Dawah Pharma LLC (USA) and Bateel Group Holding Read More Dr. Hossam Abdel Maqsoud Hosts Diplomatic Dinner Celebrating the Appointment of Ambassador Mohamed El-Helwany as Egypt’s Ambassador to Guinea Read More GYPTO Pharma Signs Preliminary Agreement with Mozambique Government to Establish Regional Pharmaceutical Distribution Hub Read More Egypt’s Gypto Pharma (Medicine City) and US-based Dawa Pharmaceuticals signed a strategic alliance agreement aimed at strengthening Egypt’s pharmaceutical industry and achieving US Food and Drug Administration (FDA) qualification for Gypto Pharma’s facilities Read More

We deliver care that connects communities to a healthier future. Dawah Pharmaceuticals is redefining access to essential medicine through a global platform built on science, trust, and collaboration. With a presence in the U.S., Egypt, and across the MENA region, our commitment goes beyond manufacturing "Filling the Gap" Dawah Pharmaceuticals is committed to addressing critical shortages in sterile injectable medications by bringing essential, FDA-compliant drugs to market. Through strategic partnerships with top-tier Contract Manufacturing Organizations (CMOs), we ensure a timely response to the healthcare industry's pressing needs. "Innovative Outsourcing Models" Leveraging our partnerships with global CMOs, Dawah Pharmaceuticals focuses on efficient, high-quality drug production without the constraints of traditional manufacturing. This approach allows us to accelerate timelines and maintain flexibility, ensuring that critical medications reach patients faster. "Strategic Growth and Market Entry" Our portfolio includes high-priority products produced exclusively through CMOs. By prioritizing collaboration and scalability, Dawah is building a sustainable framework to expand its market presence and deliver impactful solutions across multiple therapeutic areas. "Injectable and ophthalmic pharmaceutical company" We market and manufacture a growing portfolio of FDA-approved medicines, including several generic alternatives, in the United States. Our products include both injectable and ophthalmic prescription medicines. Explore Our Products Trusted pharmaceutical solutions designed with science View More ABOUT DAWAH Dawah Pharmaceuticals is a U.S.-based pharmaceutical company with a global vision and deep regional roots. Backed by over 30 years of leadership experience in healthcare, Dawah bridges U.S. regulatory expertise with Egyptian manufacturing excellence to deliver quality medicines worldwide. Through its strategic joint ventures Dawah-Gypto Pharma and Dawah-Holdi Pharma the company operates internationally accredited facilities producing over 200 million units annually. Dawah’s diverse portfolio spans sterile injectables, oral medications, and wellness products, all aligned with the highest global standards. Headquartered in the United States with an expanding footprint across Egypt and the MENA region, Dawah Pharma is committed to advancing quality, affordability, and access to care across continents. Our Team Contact Us Submit

Our Approach Dawah Pharmaceuticals Inc. is a modern pharmaceutical company committed to expanding access to high-quality sterile injectables, ophthalmic products, and IV solutions. We follow an innovative operating model that focuses on strategic outsourcing and deep industry expertise, rather than traditional in-house manufacturing. Through partnerships with leading global Contract Manufacturing Organizations, we consistently deliver FDA-compliant medicines with efficiency, precision, and exceptional quality. Our product portfolio includes more than twenty-five essential treatments across anesthesia, oncology, critical care, and ophthalmology, addressing key needs in global healthcare. Our leadership team brings over two centuries of combined experience from top pharmaceutical institutions across the United States, Europe, and India. This strong foundation enables us to identify emerging opportunities, accelerate product development, and navigate regulatory environments with confidence and clarity. At Dawah Pharmaceuticals, we unite strategic vision, scientific expertise, and global partnerships to build a scalable and agile platform that supports patients and healthcare systems worldwide. Dawah Pharmaceuticals: Vision, Innovation, and Strategic Excellence Meeting Global Challenges Dawah Pharmaceuticals is committed to closing critical gaps in global drug supply, with a special focus on sterile dosage forms that are essential across the United States, Europe, the Middle East, and Africa. Through deep market intelligence and a strong network of world-class manufacturing partners, we deliver reliable pharmaceutical solutions that support global healthcare systems and ensure adherence to international quality standards. Innovating for the Future Our product portfolio features advanced formulations including liposomal therapies, biosimilars, and preservative-free ophthalmic products. These innovations address major therapeutic needs in oncology, antifungal treatment, and ocular care, offering improved patient outcomes, enhanced safety profiles, and greater treatment compliance. Strategic Foundations of Dawah Pharmaceuticals Outsourcing Excellence We collaborate with leading Contract Manufacturing Organizations to maintain flexibility, optimize production, and ensure delivery of high-quality, FDA-compliant medicines. Regulatory Strength Our experienced regulatory team expertly manages U.S. and global regulatory submissions, enabling efficient approval pathways and faster access to essential medications. Market Driven Strategy By continuously monitoring global healthcare trends, we identify promising therapeutic areas and adapt our development priorities to meet emerging patient and market needs. At Dawah Pharmaceuticals, we are driven by innovation, strategic partnerships, and a commitment to patient-focused excellence. Our goal is to shape the future of global healthcare and deliver meaningful value to communities around the world.

Dr. Hossam Abdel Maqsoud Hosts Diplomatic Dinner Celebrating the Appointment of Ambassador Mohamed El-Helwany as Egypt’s Ambassador to Guinea Dr. Hossam Abdel Maqsoud, Chairman of Dawah Pharma USA and Board Member of the Egyptian African Businessmen Association, hosted a dinner at the Diplomatic Club in honor of the appointment of Ambassador Mohamed El-Helwany as Egypt’s Ambassador to the Republic of Guinea The event was attended by distinguished figures from the diplomatic, economic, and media sectors, including: Dr. Abdelhakim El Waer, Assistant Director-General and Regional Representative for the Near East and North Africa – FAO H.E. Sim Monir Cisse, Ambassador of Guinea to Egypt Dr. Yousry El Sharkawy, President of the Egyptian African Businessmen Association Eng. Ahmed Al Assar, Chairman of Massar Mr. Magdy Mounir, Editor-in-Chief at Al-Ahram Dr. Wael Youssef, CEO of Al Nasr Export & Import Mr. Willy Dowlaty, Vice Chairman of Taamir Mr. Ahmed Yassin, Vice Chairman of Dawah Pharma Mr. Karim Ismail, Chairman of Scope Sports and Board Member of the Association Eng. Ahmed Samir, Board Member of the Association During the event, Dr. Abdel Maqsoud highlighted the company’s strong growth strategy across Africa, aiming to expand the presence of high-quality Egyptian pharmaceuticals into new markets—both across the African continent and from Egypt into the United States He also emphasized that Dawah Pharma is actively working towards securing U.S. FDA approval to reinforce global trust in Egyptian medical products and strengthen Egypt’s position as a key player in the international pharmaceutical industry

Egypt Signs Strategic Tripartite Partnership to Build an Integrated Medical Manufacturing Ecosystem for Regional & Global Markets Engineer Mohamed Shimi, Minister of Public Business Sector, witnessed the signing of a major tripartite partnership between Dawah Holding International (Egypt), Dawah Pharma LLC (USA), and QG Medical Devices (Qatar-Germany) at the Ministry’s headquarters in the New Administrative Capital. The ceremony was attended by the heads of the Egyptian Drug Authority (EDA) and the Unified Procurement Authority, along with senior company representatives. This agreement aims to establish a fully integrated ecosystem for the manufacturing and supply of pharmaceuticals and medical devices, reinforcing Egypt’s position as a regional hub serving Arab and global markets. It supports national efforts to localize advanced medical technologies, expand exports, and enhance regional health security The Minister emphasized that the partnership represents a key step toward modernizing the pharmaceutical industry within state-affiliated companies, supporting Egypt’s Vision 2030 to boost industrial investment, strengthen pharmaceutical security, and enhance the global competitiveness of Egyptian and Arab products Dr. Ali El-Ghamrawy, Chairman of the EDA, highlighted the Authority’s role as a strategic partner in fostering investment and localizing medical supplies manufacturing to build a strong national industry capable of competing globally Dr. Hisham Sayed Sitet, Chairman of the Unified Procurement Authority, stated that the agreement supports the creation of a unified Arab medical supply system offering high quality products at competitive prices From the private sector side, Dr. Hossam Abdel-Maksoud, Chairman and CEO of Dawah Pharma LLC, described the partnership as “a foundation for an Arab-international healthcare alliance that drives innovation and knowledge exchange.” Mr. Fahd Abdullah Malik, Vice Chairman of QG Medical Devices, said the collaboration opens new opportunities for medical manufacturing cooperation between Qatar, Egypt, and the U.S The partnership reflects a shared vision of “Health Without Borders”, with industrial and scientific projects that expand across Egypt, Africa, and the Arab region aligned with Egypt’s and Qatar’s national development goals

توماس إنغالينيرا نائب الرئيس للعمليات يشغل الدكتور توماس إنغالينيرا منصب نائب الرئيس للعمليات، ويملك أكثر من 40 عامًا من الخبرة في البحث والتطوير الدوائي، مع تخصص في أشكال الجرعات القابلة للحقن. يقدم الدكتور إنغالينيرا القيادة التقنية والعلمية عبر برامج تطوير الأدوية، داعمًا المشاريع منذ مرحلة ما قبل التكوين وحتى الإنتاج التجاري الكامل. وقد شغل مناصب عليا في مؤسسات عالمية رائدة، بما في ذلك Pharmaceutics International، وBioCryst Pharmaceuticals، وParenta Pharmaceuticals، وAAI Pharma، وGenzyme، وBurroughs Wellcome، وA.H. Robins. يحمل شهادة بكالوريوس العلوم في الصيدلة ودكتوراه في الصيدلة من جامعة فيرجينيا كومنولث. وبالإضافة إلى دوره التنفيذي، يعمل الدكتور إنغالينيرا عضوًا في مجموعة الاستشارات التقنية لمؤسسة بيل وميليندا غيتس، مساهماً بخبراته في المبادرات الصحية العالمية.